Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)

 
• By Jessica Merrill

The US launch of Pfizer's Inflectra has been an early case study for the US biosimilar market, and some biosimilar manufacturers and payers say market access challenges are worrying.

Businessman
Remicade biosimilar case reveals cavernous market challenges • Source: Shutterstock

More from Drug Pricing

More from Scrip